Kohei Kushiro

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota et al. · Frontiers in Oncology · 2021 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

Kohei Kushiro, Satoshi Watanabe, Yuka Goto et al. · Translational Lung Cancer Research · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto et al. · Cancers · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).

Mao Uematsu, Yoko Tsukita, Takehiro Tozuka et al. · Journal of Clinical Oncology · 2023 · 10 citations

Medicine, Oncology, Pharmacotherapy +17